Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases - PubMed

Affiliations

• PMID: 18723062
• DOI: 10.1016/j.vaccine.2008.07.096

Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases

Paolo Bonanni et al. Vaccine. 2008.

Abstract

An economic evaluation of universal varicella vaccination in Italy was performed to assess the potential clinical and economic effects of three different strategies versus no vaccination. By means of the EVITA model, vaccination with two doses in toddlers only (1-1.5 years), adolescents only (13 years) and toddlers with adolescents catch-up programmes were simulated. All universal varicella vaccination strategies including toddlers (with or without an adolescent catch-up programme) turned out to be highly effective in reducing the burden of disease due to varicella. In addition, they lead to significant net savings from the societal perspective but to higher costs compared to return of investment from National Health Service perspective. The huge economic burden of hospitalised uncomplicated varicella cases registered in Italy can partially explain these highly beneficial findings for the societal perspective. Overall, our analysis confirmed the favourable clinical and economic impact of routine varicella vaccination with two doses of vaccine in Italy.

Similar articles

• [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].

  Knuf M, Neiss A, Wutzler P. Knuf M, et al. Klin Padiatr. 2006 Jul-Aug;218(4):203-12. doi: 10.1055/s-2005-836610. Klin Padiatr. 2006. PMID: 16819701 German.

• Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.

  Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Wutzler P, et al. Med Microbiol Immunol. 2002 Oct;191(2):89-96. doi: 10.1007/s00430-002-0123-4. Epub 2002 Aug 29. Med Microbiol Immunol. 2002. PMID: 12410347

• Varicella vaccination in Italy : an economic evaluation of different scenarios.

  Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Coudeville L, et al. Pharmacoeconomics. 2004;22(13):839-55. doi: 10.2165/00019053-200422130-00003. Pharmacoeconomics. 2004. PMID: 15329030

• Clinical and economic considerations of vaccination against varicella.

  Strassels SA, Sullivan SD. Strassels SA, et al. Pharmacotherapy. 1997 Jan-Feb;17(1):133-9. Pharmacotherapy. 1997. PMID: 9017774 Review.

• Varicella vaccination in Australia.

  Macartney KK, Beutels P, McIntyre P, Burgess MA. Macartney KK, et al. J Paediatr Child Health. 2005 Nov;41(11):544-52. doi: 10.1111/j.1440-1754.2005.00717.x. J Paediatr Child Health. 2005. PMID: 16398834 Review.

Cited by

• Economic evaluation of Varicella vaccination: results of a systematic review.

  Unim B, Saulle R, Boccalini S, Taddei C, Ceccherini V, Boccia A, Bonanni P, La Torre G. Unim B, et al. Hum Vaccin Immunother. 2013 Sep;9(9):1932-42. doi: 10.4161/hv.25228. Epub 2013 Jul 3. Hum Vaccin Immunother. 2013. PMID: 23823940 Free PMC article. Review.

• Economic burden of varicella in Europe in the absence of universal varicella vaccination.

  Pawaskar M, Méroc E, Samant S, Flem E, Bencina G, Riera-Montes M, Heininger U. Pawaskar M, et al. BMC Public Health. 2021 Dec 21;21(1):2312. doi: 10.1186/s12889-021-12343-x. BMC Public Health. 2021. PMID: 34930179 Free PMC article.

• The societal role of lifelong vaccination.

  Postma MJ, Carroll S, Brandão A. Postma MJ, et al. J Mark Access Health Policy. 2015 Aug 12;3. doi: 10.3402/jmahp.v3.26962. eCollection 2015. J Mark Access Health Policy. 2015. PMID: 27123178 Free PMC article.

• Successes and challenges in varicella vaccine.

  Papaloukas O, Giannouli G, Papaevangelou V. Papaloukas O, et al. Ther Adv Vaccines. 2014 Mar;2(2):39-55. doi: 10.1177/2051013613515621. Ther Adv Vaccines. 2014. PMID: 24757524 Free PMC article. Review.

• The Economic Value of Vaccination: Why Prevention is Wealth.

  [No authors listed] [No authors listed] J Mark Access Health Policy. 2015 Aug 12;3. doi: 10.3402/jmahp.v3.29414. eCollection 2015. J Mark Access Health Policy. 2015. PMID: 27123186 Free PMC article. No abstract available.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information